AstraZeneca strengthens collaboration in immuno-oncology

23 October 2018

AstraZeneca (LSE: ANZ) and its global biologics research and development arm MedImmune are expanding their presence in the competitive immuno-oncology (I-O) with a new deal and equity stake in a French biotech firm.

The Anglo-Swedish pharma major today announced a new multi-term agreement with Innate Pharma (Euronext Paris: IPH), with the news sending the latter’s share rocketing 29.12% to 6.18 euros. This builds on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly.

AstraZeneca will obtain full oncology rights to the first-in-class humanized anti-NKG2A antibody, monalizumab, expanding its partnership with Innate from the initial collaboration announced in 2015. AstraZeneca also gains option rights to IPH5201, an antibody targeting CD39, as well as four preclinical molecules from Innate’s pipeline. Innate is licensing the US and EU commercial rights to recently Food and Drug Administration-approved Lumoxiti (moxetumomab pasudotox) for hairy cell leukemia (HCL).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK